RapidAI Receives FDA Clearance of Rapid SDH for Detection Of Hemispheric Subdural Hematomas

RapidAI has received FDA clearance of Rapid SDH, its AI-powered module for the detecting and reporting suspected hemispheric acute and chronic subdural hematoma. Together with Rapid ICH and Rapid Hyperdensity, the three modules comprise RapidAI’s unique and industry-leading hemorrhagic and trauma care AI solution, designed to help teams on the front lines of patient assessment streamline decision making and expedite patient care.

Rapid SDH leverages AI and the intelligence gained from analyzing hundreds of patient scans to help neurocritical care teams identify suspected hemispheric subdural hemorrhage faster and with a higher degree of accuracy than traditional methods. With the advanced Rapid mobile app, Rapid SDH automatically sends results to the entire trauma team across the hospital system or treatment network, enabling clinicians to make more timely and informed transfer and treatment decisions for patients with traumatic brain injury or hemorrhagic stroke.

The FDA’s clearance of Rapid SDH significantly enhances our expanding range of hemorrhagic and trauma care solutions at this crucial time of rapidly growing patient numbers, clinician shortages, and advancements in potential treatment options,” said Amit Phadnis, CTO of RapidAI.

To view the source version, please click HERE.

en_GBEnglish (UK)